More than 1 in 10 adults worldwide is affected by chronic kidney disease (CKD), making it one of the leading causes of death globally. While a wide range of conditions can lead to chronic kidney failure, they all converge on a common pathological process: fibrosis, the progressive scarring of kidney tissue. Despite its central role in disease progression, effective anti-fibrotic therapies for broad use in CKD patients are still lacking. As part of the RevOFib (“Reversal of Fibrosis”) project, the scientists are developing a portfolio of first-in-class small molecules and antisense oligonucleotides (ASOs) targeting renal fibrosis — the final common pathway in CKD. Funding from ForTra will support the first-in-human clinical trial of the lead anti-fibrotic candidate, GO102.

Further information here.